Trillium Therapeutics

Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides. It involves in therapeutic areas, including autoimmune disease, cancer, necrotizing enterocolitis, and transplantation. Trillium Therapeutics Inc. was formerly known as Transplantation Technologies Inc. and changed its name in May 2003. The company was founded in 1996 and is based in Toronto, Canada.

Forty Seven Inc

Gilead Sciences

Gilead Sciences and Forty Seven are reportedly tying the knot through a $4.9 billion buyout agreement. Shares of Trillium Therapeutics, a fellow CD47 drugmaker, are also jumping on this news.

Why Gilead Sciences, Forty Seven, and Trillium Therapeutics Are Moving Higher Today

Co-Diagnostics

Vir Biotechnology

Small-cap biotechs focused on virus treatments and cures have soared in recent weeks, but most folks should avoid these risky stocks.

Small-Cap Biotech Stocks Soar on Coronavirus Speculation

CAMBRIDGE, Mass., Feb.  28, 2020  (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the “Company”) (NASDAQ/TSX: TRIL) wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its common shares.

Trillium Therapeutics Responds to Market Activity

Trillium Is An Undervalued, Misunderstood Biotech With Significant Upside In 2020

CAMBRIDGE, Mass., Feb.  07, 2020  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of Directors, and Dr. Ali Behbahani has been appointed as a Board Observer, effective February 6, 2020. 

Trillium Therapeutics Announces Changes to Its Board of Directors

Johnson & Johnson

Pulmatrix

Vaxart

January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.

The Wining Sector & Its Top Stocks in Virus-Infected January

CAMBRIDGE, Mass., Jan.  29, 2020  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 41,279,090 common shares of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares of the Company (the “Offering”). The common shares and preferred shares were sold at a public offering price of US$2.75 per share. The number of shares sold includes the full exercise by the underwriters of their option to purchase up to an additional 5,547,272 common shares.

Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

CAMBRIDGE, Mass., Jan.  23, 2020  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 35,731,818 common shares (the “Common Shares”) of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares (the “Series II First Preferred Shares”) of the Company (the “Offering”). The Common Shares are being sold at a public offering price of US$2.75 per Common Share and the Series II First Preferred Shares are being sold at a public offering price of US$2.75 per Series II First Preferred Share.

Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

CAMBRIDGE, Mass., Jan.  22, 2020  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of common shares (the “Common Shares”) of the Company and Series II Non-Voting Convertible First Preferred Shares (the “Series II First Preferred Shares”) of the Company (the “Offering”). In addition, Trillium intends to grant the underwriters a 30-day option to purchase up to an additional amount of Common Shares equal to 15% of the Common Shares and Series II First Preferred Shares offered in the Offering.

Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

Trillium Therapeutics: This Underdog In The CD47 Space Is Staging A Comeback

Trillium Therapeutics: Under New Management And Advancing Dual CD-47 Targets

Shares of Trillium Therapeutics Inc. TRIL, +90.93% nearly doubled in very active trading Thursday, after the developer of cancer treatments provided an upbeat update on its TTI-621 and TTI-622 programs.

Trillium Therapeutics' stock rockets on heavy volume after an upbeat update on cancer-treatment programs

CAMBRIDGE, Mass., Jan.  07, 2020  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update on its TTI-621 and TTI-622 clinical programs.

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Trillium (TRIL) Stock?

TORONTO, Nov.  14, 2019  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September 30, 2019, and provided a corporate update.

Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

TORONTO, Oct.  22, 2019  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium, "the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced corporate restructuring to extend the company’s cash runway and to focus on critical value-creating activities. The company also provided an update on its clinical development and research programs.

Trillium Therapeutics Announces Corporate Restructuring and Provides CD47 Program Update

TORONTO, Oct.  08, 2019  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is eligible for an additional 180 calendar day period to regain compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market (the “Exchange”).

Trillium Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule

Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer

TORONTO, Sept.  05, 2019  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present at the following upcoming investor conference:

News for Trillium Therapeutics Stock (TRIL)